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Purpose: Partial nephrectomy (PN) for patients with T1a renal cell carcinoma (RCC) 
has increasingly become accepted, although its role for patients with T1b RCC remains 
controversial. We retrospectively evaluated and then compared the oncologic and func-
tional outcomes of patients with pT1b RCC who were treated with PN or radical neph-
rectomy (RN).
Materials and Methods: A total of 70 patients who were diagnosed with pT1bN0M0 
RCC between January 1995 and December 2004 were included. The 5-year overall sur-
vival (OS), the 5-year recurrence-free survival (RFS), and the 5-year cancer-specific sur-
vival (CSS) were compared between the groups. Preoperative and postoperative serum 
creatinine and estimated glomerular filtration rate (GFR) levels were analyzed to as-
sess renal function.
Results: The 5-year OS (92.3% vs. 87.8%, p=0.501), RFS (92.3% vs. 77.8%, p=0.175), and 
CSS (92.3% vs. 94.5%, p=0.936) of the PN and RN groups were not statistically different. 
The proportion of patients with decreased renal function was lower in the PN group than 
in the RN group (PN=0% vs. RN=11.5%). The postoperative change in serum creatinine 
and the GFR 1 year after nephrectomy was higher in the RN group than in the PN group 
(PN=0.2±0.2, 12.1±9.1 vs. RN=0.3±0.5, 18.1±12.5), but there was no statistical difference.
Conclusions: There were no statistically significant differences in prognosis or renal 
function between patients treated with PN and those treated with RN for pT1b RCC. 
PN may be a useful treatment modality for patients with pT1b RCC.
Key Words: Nephrectomy; Prognosis; Renal cell carcinoma
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Article History:
received 27 May, 2010
accepted 17 August, 2010
Corresponding Author:
Hyun Tae Kim
Department of Urology, College of 
Medicine, Yeungnam University, 
317-1, Daemyeong 5-dong, 
Nam-gu, Daegu 705-035, Korea
TEL: +82-53-620-3694
FAX: +82-53-627-5535
E-mail: htkim@ynu.ac.kr
INTRODUCTION
The main treatment for renal cell carcinoma (RCC) is radi-
cal nephrectomy (RN), and RN has been the gold standard 
treatment for RCC during the last 2 decades [1]. However, 
the risk of deteriorated renal function after RN has now been 
well documented [2]. The incidental detection of renal mass-
es has dramatically increased the number of patients pre-
senting with locally confined RCC, and this calls for multi-
ple options for the surgical therapy [3]. Consequently, there 
has been a continuous development of partial nephrectomy 
(PN) to avoid unnecessary destruction of nephrons [3,4]. 
　The benefits of PN include a decreased risk of long-term 
renal insufficiency and a positive impact on the quality of 
life [5-7]. Thus, according to the current guidelines, PN is 
now indicated for RCC less than 4 cm [1]. Although earlier 
studies suggested that 4 cm be established as the max-
imum size for PN [1], recent data suggest that it might be 
possible to extend the success and benefits of PN to treating 
tumors ＞4 cm in size [3,8].
　Thus, we retrospectively evaluated and compared the 
oncologic and functional outcomes of patients treated with 
PN and RN for pT1b stage RCC.
MATERIALS AND METHODS
1. Patients
A total of 70 patients who were diagnosed with pT1bN0M0 Korean J Urol 2010;51:596-600
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TABLE 1. Characteristics of the patients with pT1b renal cell carcinoma
PN (n=18) RN (n=52)  p-value
Age (years) 47.3±9.8  57.3±10.7 0.001
a
Sex 0.811
b
  Male (%) 13 (72.2) 36 (69.2)
  Female (%) 5 (27.8) 16 (30.8)
Diabetes mellitus (%) 3 (16.7) 5 (9.6) 0.415
b
Hypertension (%) 2 (11.1) 10 (19.2) 0.718
b
Charlson comorbidity index score 0.883
b
  0 (%) 10 (55.5) 26 (50.0)
  1 (%) 4 (22.2) 17 (32.7)
  2 (%) 3 (16.7) 6 (11.5)
  ≥3 (%) 1 (5.6) 3 (5.8)
Follow-up duration (months) 78.2±44.1 66.5±43.6 0.310
a
Body mass index (kg/m
2) 23.1±2.6 23.8±2.8 0.341
a
Preoperative symptoms (%) 7 (38.9) 21 (40.4) 0.974
b
  Flank pain (%) 6 (33.3) 11 (21.2)
  Gross hematuria (%) 0 (0) 9 (17.3)
  Palpable mass (%) 1 (5.6) 1 (1.9)
Tumor size (cm) 5.0±0.9 5.5±0.9 0.036
a
  4＜size≤5 (%) 11 (61.1) 21 (40.4)
  5＜size≤6 (%) 5 (27.8) 19 (36.5) 0.348
b
  6＜size≤7 (%) 2 (11.1) 12 (23.1)
Tumor location 0.473
b
  Upper pole (%) 6 (33.3) 22 (42.3)
  Mid pole (%) 3 (16.7) 13 (25.0)
  Lower pole (%) 9 (50.0) 17 (32.7)
Histologic type 0.598
b
  Clear cell (%) 13 (72.2) 43 (82.7)
  Papillary (%) 3 (16.7) 6 (11.5)
  Others (%) 2 (11.1) 3 (5.8)
Fuhrman's nuclear grade 0.417
b
  Grade 1＋2 (%) 11 (61.1) 25 (48.1)
  Grade 3＋4 (%) 7 (38.9) 27 (51.9)
PN: partial nephrectomy, RN: radical nephrectomy, 
a: Mann-Whitney U test, 
b: Fisher’s exact test
RCC between January 1995 and December 2004 were in-
cluded in this study. All of the patients underwent PN 
(n=18, 25.7%) or RN (n=52, 74.3%) by an experienced sur-
geon, and standard techniques were used for both PN 
(under the cold ischemic condition) and RN. All of the pa-
tients underwent surgery with an open method. The pre-
operative clinical tumor staging workup included com-
puted tomography (CT) or magnetic resonance imaging 
(MRI) of the abdomen and pelvis and chest radiography. 
2. Preoperative and postoperative evaluations 
The patients’ age, gender, past medical history (diabetes 
mellitus, hypertension), Charlson comorbidity index score, 
follow-up duration, body mass index (BMI), preoperative 
symptoms, and pathologic factors (tumor size, location, his-
tologic type, and Fuhrman’s nuclear grade) were investi-
gated. To identify the oncologic outcome, the 5-year overall 
survival (OS), 5-year recurrence-free survival (RFS), and 
5-year cancer-specific survival (CSS) were compared be-
tween each group. To evaluate renal function, the pre-
operative and postoperative (immediate and 1 year after 
nephrectomy) serum creatinine level and estimated glo-
merular filtration rate (GFR) were analyzed. The esti-
mated GFR was calculated by using the Modification of Diet 
in Renal Disease (MDRD) equation.
3. Follow-up evaluations
All the patients received a follow-up visit at 1 to 2 weeks 
after discharge for assessing their general health status. 
After the first visit, the patients received follow-up evalua-
tions every 3 or 6 months until the first year, and then 
annually. At these times, they were evaluated for newly de-
veloped symptoms and they underwent careful physical ex-
aminations, laboratory tests, and radiologic tests (chest 
X-ray, ultrasonography [USG], CT). The USG, CT, and/or 
MRI were checked to evaluate for local recurrence or dis-
tant metastasis. 
4. Definition
The stage was reassessed according to the 2002 TNM clas-
sification system [9]. Decreased renal function was eval-
uated according to the National Kidney Foundation Korean J Urol 2010;51:596-600
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FIG. 1. Kaplan-Meier survival curve estimates of the 5-year overall 
survival for all patients according to whether they underwent 
partial nephrectomy or radical nephrectomy.
FIG. 2. Kaplan-Meier survival curve estimates of the 5-year 
recurrence-free survival for all patients according to whether 
they underwent partial nephrectomy or radical nephrectomy.
FIG. 3. Kaplan-Meier survival curve estimates of the 5-year 
cancer- specific survival for all patients according to whether they
underwent partial nephrectomy or radical nephrectomy.
TABLE 2. Local recurrence and distant metastasis in patients 
with pT1b renal cell carcinoma
Partial 
nephrectomy
(n=18)
Radical 
nephrectomy
(n=52)
Local recurrence
Distant metastasis
Lung
Bone
Liver
Brain
0 (0)
1 (5.5)
1 (5.5)
0 (0)
0 (0)
0 (0)
0 (0)
9 (17.3)
4 (7.7)
3 (5.8)
1 (1.9)
1 (1.9)
Dialysis Outcomes Quality Initiative Clinical Practice 
Guidelines [10]. The endpoints consisted of OS, RFS, and 
CSS. Cancer-specific mortality was defined as death pri-
marily caused by metastatic RCC. Recurrence was defined 
as radiologically identified metastasis or local recurrence 
during the study period.
5. Analysis
The 5-year OS, RFS, and CSS were estimated by using the 
Kaplan-Meier method. The effect of surgery on renal func-
tion, according to the serum creatinine levels and esti-
mated GFR, was analyzed by using the Mann-Whitney U 
test. A 5% level of significance was used for all statistical 
testing, and all statistical tests were two-sided. The analy-
sis was performed by using the statistical software SPSS 
(17.0KO for Windows, release 14.0.2).
RESULTS
The mean ages of the patients were 47.3±9.8 years and 
57.3±10.7 years for the PN and RN groups, respectively. 
The mean follow-up durations of the patients treated with 
PN and RN were 78.2±44.1 months and 66.5±43.6 months, 
respectively. The characteristics of the 70 patients with 
pT1b RCC are shown in Table 1. 
　The 5-year OS rate (92.3% vs. 87.8%, p=0.501), the 5-year 
RFS rate (92.3% vs. 77.8%, p=0.175), and the 5-year CSS 
rate (92.3% vs. 94.5%, p=0.936) for the PN and RN groups 
showed no significant difference (Fig. 1-3).
　One patient (5.5%) and 9 patients (17.3%) showed dis-
tant metastasis in the PN and RN groups, respectively. 
Details of distant metastasis are summarized in Table 2.
　When comparing the renal function of the PN and RN 
groups, the proportion of patients with decreased renal 
function in the RN group was higher than that in the PN 
group (PN=0% vs. RN=11.5%). The postoperative change 
(1 year after nephrectomy) in the serum creatinine level 
was greater in the RN group than in the PN group 
(PN=0.2±0.2 mg/dl vs. RN=0.3±0.5 mg/dl, p=0.150). The 
postoperative change (1 year after nephrectomy) in the es-
timated GFR was also greater in the RN group than in the Korean J Urol 2010;51:596-600
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TABLE 3. Changes in postoperative renal function of the patients with pT1b renal cell carcinoma
PN (n=18) RN (n=52) p-value
a
Patients with increased CKD stage (n)
Mean preoperative sCr (mg/dl)
Mean postoperative sCr (immediate) (mg/dl)
Mean postoperative sCr (after 1 year) (mg/dl)
Mean change in the sCr (after 1 year) (mg/dl)
Mean preoperative eGFR (ml/min/1.73 m
2)
Mean postoperative eGFR (immediate) (ml/min/1.73 m
2)
Mean postoperative eGFR (after 1 year) (ml/min/1.73 m
2)
Mean change in the eGFR (after 1 year) (ml/min/1.73 m
2)
0 
1.0±0.2
1.3±0.3
1.2±0.2
0.2±0.2
86.0±20.0
65.4±18.3
73.9±12.8
12.1±9.1
6
1.0±0.2
1.4±0.8
1.3±0.6
0.3±0.5
81.2±19.9
57.7±12.2
63.1±16.2
18.1±12.5
0.782
0.826
0.460
0.150
0.481
0.111
0.056
0.162
PN: partial nephrectomy, RN: radical nephrectomy, CKD: chronic kidney disease, sCr: serum creatinine, eGFR: estimated glomerular
filtration rate, 
a: Mann-Whitney U test
PN group (PN=12.1±9.1 ml/min/1.73 m
2 vs. RN=18.1±12.5 
ml/min/1.73 m
2, p=0.162), but the difference was statisti-
cally insignificant (Table 3). 
DISCUSSION
RN has generally remained the standard treatment for lo-
calized RCC for many decades because of concern about in-
complete tumor excision, local recurrence, microscopic sat-
ellite tumors, and multifocality. Initially, PN was accepted 
as the standard treatment of only localized RCC with im-
perative or absolute indications (patients with a solitary 
kidney or bilateral RCC). The relative indications are a 
functioning contralateral kidney that is affected by co-
morbidities that might impair future renal function, such 
as diabetes, arterial hypertension, and arteriosclerosis, in-
cluding the hereditary forms of RCC. Elective indications 
are those for a perfectly normal contralateral kidney 
[11,12]. 
　With the widespread use of advanced diagnostic imaging 
techniques such USG, CT, and MRI, a large number of re-
nal masses are being incidentally found before they pro-
duce symptoms [13]. This has led to a migration of RCC cas-
es toward earlier stages [14]. RN has a risk of renal function 
deterioration. Several studies have suggested that RN is 
a significant risk factor for the development of chronic kid-
ney disease. Huang et al reported that the risk of new onset 
of chronic kidney disease is significantly greater in pa-
tients undergoing RN than in those undergoing PN [15]. 
PN provides multiple options for surgically treating renal 
tumors [3], and during the last decade the urological com-
munity has come to accept PN as a safe, effective alter-
native to RN in elective situations. According to the 2007 
RCC guidelines of the European Association of Urology, PN 
is the standard treatment for patients with clinically lo-
calized RCC ≤4 cm (T1a tumors) [1]. Just as PN for T1a 
tumors has become well accepted, physicians are now rais-
ing the issue of expanding the indications for elective PN 
to include larger tumors. 
　Several studies have suggested that the indications for 
PN can be safely expanded to include patients with RCC 
up to 7 cm (T1b tumors) [16-18]. Leibovich et al have re-
ported 5-year CSS rates of 95% and 98% for patients with 
tumors measuring 4 to 7 cm and who underwent PN and 
RN, respectively [3]. Patard et al reported 3-year CSS rates 
of 98% and 97% for patients who underwent PN for tumors 
＜4 and ＞4 cm, respectively [19]. These data justify the use 
of nephron-sparing surgery for larger, anatomically ame-
nable tumors. 
　Another advantage of PN includes preservation of the 
maximum renal parenchyma, which help to avoid end- 
stage renal disease and positively impacts the quality of life 
[7,20]. Chronic renal failure and dialysis are associated 
with significant cardiovascular morbidity and mortality, 
and it has been suggested that RN may impact long-term 
survival compared with PN for renal tumors [15]. Weight 
et al have reported that the average excess loss of renal 
function observed with RN was associated with a 25% in-
creased risk of cardiac death and 17% increased risk of 
death from any cause in a multivariate analysis [21]. 
Thompson et al reported that PN decreases the risk of 
chronic renal failure and complications including hip frac-
tures and cardiovascular morbidity [22]. Lesage et al re-
cently compared open PN and RN for renal tumors, and 
they concluded that the former resulted in a better quality 
of life due to the preservation of renal function [20]. Dash 
et al compared the outcomes of elective PN vs. RN for clear 
cell RCC 4 to 7 cm in size. They showed that renal function 
was better preserved after PN and that there was no clear 
evidence that PN was associated with an inferior onco-
logical outcome [8]. Furthermore, the results of a recent ret-
rospective study have shown that in selected patients with 
stage T1b-T3N0M0 RCC ＞4 cm in size, laparoscopic PN 
provides intermediate-term oncological efficacy equiv-
alent to that of laparoscopic RN and the renal function out-
comes are superior to that of laparoscopic RN [23]. 
　In this study, PN and RN showed similar results for OS 
(92.3% vs. 87.8%, p=0.501), RFS (92.3% vs. 77.8%, p=0.175), 
and CSS (92.3% vs. 94.5%, p=0.936), respectively. Further-
more, the proportion of patients with decreased renal func-
tion (PN=0% vs. RN=11.5%) and postoperative changes in 
the serum creatinine level 1 year after nephrectomy 
(0.2±0.2 mg/dl vs. 0.3±0.5 mg/dl, p=0.150) was better in the 
PN group than in the RN group. Thus, our results showed Korean J Urol 2010;51:596-600
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that PN is a safe and effective method for treating pT1b RCC 
and the oncologic and functional outcomes are good.
　The limitations of this study included the retrospective 
nature of the analysis, the smaller number of patients in 
the PN group (n=18), the small numbers of oncologic events 
in both groups, that it was a single-surgeon experience, and 
the intermediate duration of follow-up. Because this was 
a retrospective study, the patients were not randomly as-
signed to a surgical procedure, which meant that the choice 
of surgery might have been biased by the surgeons' prefer-
ence according to the preoperative condition of the patient. 
With time, increased patient numbers, prolonged fol-
low-up duration, and increased numbers of events will be 
available for study.
　Previous studies have demonstrated that for RCC ＞4 
cm, PN has excellent survival and recurrence rates. 
Although PN is a controversial choice for larger tumors, we 
demonstrated that pT1b patients can also be treated safely 
and they can expect an optimal long-term oncologic efficacy 
with PN. Therefore, PN is effective for patients with pT1b 
RCC and it provides long-term tumor control while pre-
serving renal function. 
CONCLUSIONS
In this study, PN for patients with pT1b RCC had no stat-
istically significant difference in prognosis compared with 
that of RN, and the renal function of the patients who un-
derwent PN was better. PN is a feasible surgical method 
for treating pT1b stage RCC.
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